Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-25T09:12:22.862Z Has data issue: false hasContentIssue false
  • English
  • Français

DOSAGE AND DURATION OF ETANERCEPT THERAPY FOR ANKYLOSING SPONDYLITIS: A META-ANALYSIS

Published online by Cambridge University Press:  24 April 2017

Heeyoung Lee ,
Younjoo Jung ,
Seungyeon Song ,
Jihyung Lee ,
Hyunjun Shim ,
Wonku Kang  and
Eunyoung Kim
Heeyoung Lee
Affiliation:
Evidence-based Research Lab, Division of Clinical Pharmacotherapy
Younjoo Jung
Affiliation:
Evidence-based Research Lab, Division of Clinical Pharmacotherapy Division of Medication information Services, Veterans Hospital
Seungyeon Song
Affiliation:
Evidence-based Research Lab, Division of Clinical Pharmacotherapy
Jihyung Lee
Affiliation:
Evidence-based Research Lab, Division of Clinical Pharmacotherapy
Hyunjun Shim
Affiliation:
The Graduate School Pharmaceutical Management, Chung-Ang University
Wonku Kang
Affiliation:
College of Pharmacy, Chung-Ang University
Eunyoung Kim
Affiliation:
Evidence-based Research Lab, Division of Clinical Pharmacotherapy The Graduate School Pharmaceutical Management, Chung-Ang University College of Pharmacy, Chung-Ang [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: We conducted a meta-analysis of recently published randomized controlled trials (RCTs) to identify the most effective and safe etanercept dosing regimen and duration of therapy for the treatment of patients with ankylosing spondylitis (AS).

Methods: We systematically reviewed PubMed, Embase, Cochrane Library, and Web of Science databases for RCTs. The proportion of patients attaining 20 percent improvement (according to the Spondyloarthritis International Society response criteria [ASAS 20]) was evaluated as a primary outcome. Secondary outcomes included 50 percent increase in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI 50) used for evaluating efficacy, as well as the BASDAI/Bath Ankylosing Spondylitis Functional Index (BASFI) scores and adverse events.

Results: ASAS 20 indicated that the efficacy of etanercept did not differ amongst dosing regimens (25 mg twice-weekly versus 50 mg once-weekly: relative risk [RR], 2.18, 95 percent confidence interval [CI], 1.78–2.67 versus RR, 2.00, 95 percent CI, 1.70–2.37). The ASAS 20 reported subgroup differences among treatment durations of less than 12 weeks (RR, 2.70; 95 percent CI, 2.09–3.49); 12 weeks (RR, 1.74; 95 percent CI, 1.37–2.22); and more than 12 weeks (RR, 2.56; 95 percent CI, 1.88–3.48). Other outcomes included BASDAI, BASDAI 50, and BASFI. Drug safety differed according to the treatment regimen and duration.

Conclusion: Our meta-analysis found that there was no significant efficacy difference between 50 mg once-weekly and 25 mg twice-weekly dosing for the treatment of AS, and a dosing duration of less than 12 weeks was more effective for treating AS patients.

Keywords

Meta-analysisEtanerceptAnkylosing spondylitisDosing regimenDuration of therapy
Type
Assessments
Information
International Journal of Technology Assessment in Health Care , Volume 33 , Issue 1 , 2017 , pp. 69 - 75
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Rudwaleit, M, Listing, J, Brandt, J, Braun, J, Sieper, J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63:665–670.CrossRefGoogle Scholar
2. Navarro-Sarabia, F, Fernandez-Sueiro, JL, Torre-Alonso, JC, et al. High-dose etanercept in ankylosing spondylitis: Results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford). 2011;50:1828–1837.CrossRefGoogle ScholarPubMed
3. Goldenberg, MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999;21:75–87; discussion 1-2.CrossRefGoogle ScholarPubMed
4. FDA/Center for Drug Evaluation and Research. Label information. Silver Spring, MD: FDA; 2013.Google Scholar
5. Maxwell, SR. Evidence based prescribing. BMJ. 2005;331:247–248.CrossRefGoogle ScholarPubMed
6. McCormack, PL, Wellington, K. Etanercept: In ankylosing spondylitis. BioDrugs. 2004;18:199–205; discussion 06.CrossRefGoogle ScholarPubMed
7. Li, ZH, Zhang, Y, Wang, J, Shi, ZJ. Etanercept in the treatment of ankylsoing spondylitis: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol. 2013;23:497–506.CrossRefGoogle Scholar
8. Baji, P, Pentek, M, Szanto, S, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: Systematic literature review and meta-analysis. Eur J Health Econ. 2014;15 (Suppl 1):S45–S52.CrossRefGoogle ScholarPubMed
9. Maxwell, LJ, Zochling, J, Boonen, A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:cd005468.Google Scholar
10. Sieper, J, Rudwaleit, M, Baraliakos, X, et al. The Assessment of SpondyloArthritis International Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68:1–44.CrossRefGoogle ScholarPubMed
11. Green, S, Higgins, JPT, Alderson, P, et al. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. p. www.Cochrane-handbook.org-www.Cochrane-handbook.org.Google Scholar
12. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. 2009;339:b2535.CrossRefGoogle ScholarPubMed
13. Moher, D, Cook, DJ, Eastwood, S, Olkin, I, Rennie, D, Stroup, DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896–1900.CrossRefGoogle Scholar
14. Egger, M, Davey Smith, G, Schneider, M, Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.CrossRefGoogle ScholarPubMed
15. Duval, S, Tweedie, R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–463.CrossRefGoogle ScholarPubMed
16. Dougados, M, Braun, J, Szanto, S, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: Results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis. 2011;70:799–804.CrossRefGoogle ScholarPubMed
17. Dougados, M, van der Heijde, D, Sieper, J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: A multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66:2091–2102.CrossRefGoogle Scholar
18. Calin, A, Dijkmans, BA, Emery, P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004;63:1594–1600.CrossRefGoogle ScholarPubMed
19. Pang, L, Wang, L, Suo, T, et al. Tumor necrosis factor-alpha blockade leads to decreased peripheral T cell reactivity and increased dendritic cell number in peripheral blood of patients with ankylosing spondylitis. J Rheumatol. 2008;35:2220–2228.CrossRefGoogle ScholarPubMed
20. JC, Davis Jr, Van Der Heijde, D, Braun, J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum. 2003;48:3230–3236.Google Scholar
21. Lin, Q, Lin, Z, Gu, J, et al. Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment. Rheumatol Int. 2010;30:317–323.CrossRefGoogle Scholar
22. van der Heijde, D, Da Silva, JC, Dougados, M, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:1572–1577.CrossRefGoogle ScholarPubMed
23. Gorman, J.D, Sack, K.E. & Davis, J.C Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002, 346 (18), 1349-56.CrossRefGoogle ScholarPubMed
24. Brandt, J, Khariouzov, A, Listing, J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48:1667–1675.CrossRefGoogle ScholarPubMed
25. Barkham, N, Coates, LC, Keen, H, et al. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis. 2010;69:1926–1928.CrossRefGoogle ScholarPubMed
26. Huang, F, Zhang, J, Huang, JL, et al. A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis. Zhonghua Nei Ke Za Zhi. 2010;49:741–745.Google ScholarPubMed
27. Taylor, WJ, Harrison, AA. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum. 2004;51:311–315.CrossRefGoogle ScholarPubMed
28. Shu, T, Chen, GH, Rong, L, et al. Indirect comparison of anti-TNF-α agents for active ankylosing spondylitis: Mixed treatment comparison of randomized controlled trials. Clin Exp Rheumatol. 2013;31:717–722.Google Scholar
29. Machado, MA, Baarbosa, MM, Almeida, AM, et al. Treatment of ankylosing spondylitis with TNF blockers: A meta-analysis. Rheumatol Int. 2013;33:2199–2213.CrossRefGoogle ScholarPubMed
30. Brandt, J, Listing, J, Haibel, H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford), 2005;44:342–348.CrossRefGoogle ScholarPubMed
31. Wallis, D, Haroon, N, Ayearst, R, Carty, A, Inman, RD. Ankylosing spondylitis and nonradiographic axial spondyloarthritis: Part of a common spectrum or distinct diseases? J Rheumatol. 2013;40:2038–2041.CrossRefGoogle ScholarPubMed
32. Bavbek, S, Ataman, S, Bankova, L, Castells, M. Injection site reaction to adalimumab: Positive skin test and successful rapid desensitisation. Allergol Immunopathol (Madr). 2013;41:204–206.CrossRefGoogle ScholarPubMed
33. Moore, Z. Meta-analysis in context. J Clin Nurs. 2012;21:2798–2807.CrossRefGoogle ScholarPubMed
Supplementary material: Image

Lee supplementary material

Figure S1

Download Lee supplementary material(Image)
Image 128.6 KB
Supplementary material: File

Lee supplementary material

Tables S1-S3

Download Lee supplementary material(File)
File 17 KB